Physician profile
Eric T Rush
NPI 1952420705
$779,311.57
in general payments reported to CMS, 2019-2025
10 companies · $152K in 2025
The $152K reported for 2025 was more than what 99% of Clinical Genetics (M.D.) providers received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58K · 2020: $75K · 2021: $81K · 2022: $94K · 2023: $140K · 2024: $179K · 2025: $152K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $284K · Consulting Fee: $115K · Travel and Lodging: $65K · Food and Beverage: $6,867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $284,051.25 |
| Consulting Fee | $115,412.50 |
| Travel and Lodging | $64,612.73 |
| Food and Beverage | $6,867.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $476,264.39 | 2019-2025 | Strensiq |
| Kyowa Kirin, INC. | $172,537.60 | 2022-2025 | Crysvita |
| Ultragenyx Pharmaceutical INC. | $87,927.38 | 2019-2023 | Crysvita |
| Ascendis Pharma Endocrinology INC | $13,125.00 | 2022-2023 | |
| Biomarin Pharmaceutical INC. | $11,104.08 | 2021-2023 | Palynziq |
| Ipsen Biopharmaceuticals, INC | $11,019.46 | 2022-2024 | Sohonos, Bylvay |
| Horizon Therapeutics Plc | $5,422.56 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $1,732.50 | 2024 | |
| Amgen INC. | $177.77 | 2019 | |
| Travere Therapeutics, INC. | $0.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Rush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.